In this episode, John Dyer discusses how Cumulus Neuroscience is moving brain measurement for dementia beyond the clinic and into patients’ homes. He explains how repeated measurements of EEG, cognition, sleep, and behavior could offer a more complete picture of brain health.

In this episode, Amy Kruse discusses her vision for investing in a broader neurotech toolbox. She explains how to separate credible brain-health products from marketing hype, and how neuromodulation could eventually allow us to shape states such as sleep, focus, and mood.

In this episode, Meron Gribetz discusses the unmet need in current depression treatment and how Inner Cosmos is developing an implanted alternative. He explains how the device works, why brain stimulation could reshape psychiatric treatment, and how questions of agency, privacy, and control become increasingly important as BCIs grow more invasive.

In this episode, Adam Caplan shares how he went from a career in Wall Street and tech entrepreneurship to building Jump Space Ventures, a specialist neurotech venture fund. He explains what drew him into neurotech, why brain-computer interfaces are attracting so much attention, and what investors are really looking for in this fast-moving space.